Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solana Company (NASDAQ: HSDT) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and other required reports. These documents offer detailed insight into Solana Company’s dual focus as a neurotech medical device issuer and a Solana-centric digital asset treasury.
In its filings, Solana Company describes its operations in the electromedical and electrotherapeutic apparatus manufacturing industry and outlines its orally applied technology platform for neurologic deficits. Quarterly and annual reports, such as the Form 10-K and Form 10-Q, present financial statements, revenue components (including staking rewards and other revenue), operating expenses, research and development costs, and unrealized gains or losses on digital assets.
Current reports on Form 8-K document material events, including the name change from Helius Medical Technologies, Inc. to Solana Company, the adoption of a Solana-focused digital asset treasury, PIPE financings, warrant issuances, stock repurchase authorizations, changes in independent registered public accounting firms, and board and governance developments. Proxy materials on Schedule 14A describe matters submitted to stockholders, such as director elections, equity incentive plan amendments, and approvals related to cryptocurrency-linked warrants.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex items such as derivative liabilities tied to stapled warrants, digital asset treasury activities, or auditor changes. Users can review real-time updates from EDGAR, track quarterly (10-Q) and annual (10-K) reports, and examine Form 4 and related disclosures of insider transactions where available, all supported by concise AI explanations that clarify terminology and context.
Solana Company (HSDT) authorized a stock repurchase program of up to $100 million of its Class A common stock. Repurchases may occur in the open market, privately negotiated transactions, block trades, accelerated share repurchases, Rule 10b5-1 trading plans, tender offers, or combinations thereof, and can be conducted in Rule 10b-18 compliant transactions. The company has no obligation to repurchase any shares and may modify, suspend, or discontinue the plan at any time.
At a special meeting on October 30, 2025, shareholders approved the election of Cosmo Jiang to the Board, and he joined the Board immediately after the meeting. On the same day, Jeffrey S. Mathiesen resigned from the Board; his resignation was not due to any disagreement and coincided with Jiang’s election. Separately, Solana Company (Hong Kong) Limited entered into an Employment Agreement with Joseph Chee effective October 30, 2025.
Solana Company (HSDT) furnished a Form 8-K under Item 7.01 to share investor materials. On November 3, 2025, the company posted an Investor Update to its website and issued a press release. These materials are attached as Exhibit 99.1 (Corporate Presentation, dated November 2025) and Exhibit 99.2 (Press Release, dated November 3, 2025) and are incorporated by reference in the 8-K.
The company states the information is furnished pursuant to Regulation FD and not deemed “filed” for purposes of Section 18 of the Exchange Act. Solana Company, formerly Helius Medical Technologies, Inc., lists its Class A Common Stock under the ticker HSDT on The Nasdaq Stock Market LLC.
Solana Co (HSDT) reported a new director appointment disclosure. Director Cosmo Jiang filed a Form 3, the initial statement of beneficial ownership, with an event date of 10/30/2025. The filing indicates no securities are beneficially owned by the reporting person at this time. It is a single‑filer submission and reflects the director relationship only, without listing any non-derivative or derivative holdings.
Solana Company (HSDT) reported the results of its October 30, 2025 special meeting. Stockholders elected Cosmo Jiang to the board and approved share issuances tied to previously issued warrants under Nasdaq Listing Rule 5635(a). They also increased the share pool under the 2022 Equity Incentive Plan by 4,000,000 shares and authorized potential adjournments.
- Quorum: 21,742,341 shares represented; 40,299,220 shares outstanding and entitled to vote as of September 26, 2025.
- Director: For 21,737,666; Withheld 4,675.
- Strategic Advisor Warrants (Pantera Capital Management LP; Summer Wisdom Holdings Limited): For 21,577,950; Against 152,144; Abstain 12,247.
- Cryptocurrency Pre‑Funded & Stapled Warrants (SOL consideration): For 20,135,405; Against 151,931; Abstain 1,455,005.
- 2022 Equity Plan increase (4,000,000 shares): For 21,420,874; Against 319,816; Abstain 1,651.
- Adjournment authority: For 21,734,015; Against 7,893; Abstain 433.
Solana Company filed an 8-K under Regulation FD to note a correction to its October 29, 2025 press release. The company clarified that, in the first sentence of the third paragraph, the amount of “SOL” held by the company as of October 29, 2025 had increased by roughly 0.1 million since its last update on October 6, 2025, not 1 million.
The corrected press release is furnished as Exhibit 99.1. The information in this report, including Exhibit 99.1, is furnished under Item 7.01, is not deemed “filed” for Section 18 liability, and is not incorporated by reference into other filings except as expressly stated.
Solana Company furnished a press release under Item 7.01 (Regulation FD) on October 20, 2025. The release is attached as Exhibit 99.1 and incorporated by reference in this report.
The Item 7.01 information, including Exhibit 99.1, is furnished and not filed, is not subject to Section 18 of the Exchange Act, and will not be incorporated into Securities Act or Exchange Act filings except by specific reference. Solana Company was formerly known as Helius Medical Technologies, Inc., and its Class A Common Stock trades on Nasdaq under HSDT.
Solana Company reported a change in its independent auditor. On October 15, 2025, Baker Tilly US, LLP resigned as the Company’s independent registered public accounting firm, and the Audit Committee approved the appointment of CBIZ CPAs P.C. as auditor for the fiscal year ending December 31, 2025.
Baker Tilly’s audit reports for 2024 and 2023 had an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. The Company states there were no disagreements and no reportable events with Baker Tilly through October 15, 2025. A confirming letter from Baker Tilly is filed as Exhibit 16.1.
Solana Company (f/k/a Helius Medical Technologies) called a virtual special meeting to vote on five proposals. The agenda includes electing one new director, authorizing share issuances upon exercise of specific warrants under Nasdaq Listing Rule 5635(a), amending the 2022 Equity Incentive Plan to add 4,000,000 shares, and permitting adjournments if needed.
Proposal 2 seeks approval for issuances upon exercise of Strategic Advisor Warrants held by Pantera Capital Management LP and Summer Wisdom Holdings Limited. Proposal 3 seeks approval for issuances upon exercise of Cryptocurrency Pre-Funded and Cryptocurrency Stapled Warrants issued for consideration in Solana (SOL) cryptocurrency. The Board unanimously recommends voting FOR the director nominee and FOR Proposals 2, 3, 4 and 5.
The meeting is fully virtual, and only stockholders of record as of September 26, 2025 may vote. Shares outstanding were 40,299,220 as of September 26, 2025. The company also disclosed one-time discretionary cash bonuses of $890,000 (CEO) and $610,000 (CFO) under side letters, which will offset any severance or similar cash amounts.
Helius Medical Technologies, Inc. is soliciting proxies for a virtual special meeting to consider five proposals including the election of one director, Nasdaq approvals for issuance of shares on exercise of warrants tied to strategic advisors Pantera Capital and Summer Wisdom and warrants tied to acceptance of Solana (SOL) cryptocurrency, and an amendment to increase available shares under the 2022 Equity Incentive Plan by 4,000,000 shares. The Board unanimously recommends voting FOR the director nominee and Proposals 2–4. The record date is September 26, 2025 and there were 40,299,220 shares outstanding on that date. The filing discloses executive compensation policies, 2024 base salaries and bonus outcomes (Bonuses paid at 83% of target), significant equity grants in 2024 (e.g., options of 808,000 shares to the CEO), and September 24, 2025 side letters providing one-time cash bonuses of $890,000 and $610,000 to the CEO and CFO respectively, offsetting other potential post-transaction payments. The document details committee structure, independence determinations, and insider trading and clawback policies.
Solana Rocket Holdings Limited and CHUNG Wai Shing jointly disclosed beneficial ownership in Helius Medical Technologies (HSDT). They report shared voting and dispositive power over 4,040,871 Class A shares, representing 9.99% of the outstanding shares based on 40,295,612 shares outstanding as of September 24, 2025. Solana Rocket directly holds 3,887,319 shares plus pre-funded warrants for up to 10,936,107 shares and cash stapled warrants for up to 14,823,426 shares. A Beneficial Ownership Blocker limits exercise of the warrants so the reporting persons are capped at 9.99% (calculated to include 153,552 shares issuable under partial exercise). The filing includes a joint filing agreement as Exhibit 99.1.